<<< i'll bet they were also sitting on quite a bit of expired product given approval came about a year later than expected in fact the broad range of development costs cited in the court papers (50-70m) may have something to do with figuring out the write down of expired inventory that was expensed as R&D >>>
Craig Wheeler answered an analyst question regarding your above comment on the FDA approval conference call. If I remember correctly he said the product has a long inventory life and didn't believe there would be any significant write-down on the inventory. Dew, can you confirm my above comment?
Market Data 
Markets 
AI
